Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to -$2.0 billion.

  • Madrigal Pharmaceuticals' Retained Earnings fell 1658.82% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 1658.82%. This contributed to the annual value of -$1.8 billion for FY2024, which is 3486.36% down from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Retained Earnings stood at -$2.0 billion, which was down 1658.82% from -$1.9 billion recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Retained Earnings registered a high of -$478.0 million during Q1 2021, and its lowest value of -$2.0 billion during Q3 2025.
  • Its 5-year average for Retained Earnings is -$1.2 billion, with a median of -$1.1 billion in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 8427.53% in 2021, then plummeted by 1658.82% in 2025.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Retained Earnings stood at -$667.3 million in 2021, then tumbled by 44.27% to -$962.7 million in 2022, then crashed by 38.81% to -$1.3 billion in 2023, then plummeted by 34.86% to -$1.8 billion in 2024, then dropped by 12.75% to -$2.0 billion in 2025.
  • Its Retained Earnings stands at -$2.0 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.9 billion for Q1 2025.